Prostate-specific antigen velocity and the detection of Gleason score 7 to 10 prostate cancer

Cancer

Volumn 110, Issue 9, 2007, Pages 1973-1978

  Punglia, Rinaa S ^a,d   Cullen, Jennifer ^b   McLeod, David G ^c   Chen, Yongmei ^b   D'Amico, Anthony V ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^c WALTER REED ARMY MEDICAL CENTER   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Cancer detection; Gleason score; Prostate cancer; Prostate specific antigen

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANTIGEN DETECTION; ANTIGEN EXPRESSION; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; ETHNICITY; FAMILY HISTORY; GLEASON SCORE; HUMAN; HUMAN CELL; HUMAN TISSUE; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PREDICTION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE SPECIFIC ANTIGEN VELOCITY;

AGED; BIOPSY; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 35648954679     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23014     Document Type: Article

References (15)

1. Bostwick DG, Burke HB, Djakiew D, et al. Human prostate cancer risk factors. Cancer. 2004;101(10 suppl):2371-2490.
2. Etzioni R, Penson DF, Legier JM, et al. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst. 2002;94:981-990.
3. Freedland SJ, Humphreys EB, Mangold LA, et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA. 2005;294:433-439.
4. Bill-Axelson A, Holmberg L, Ruutu M, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med. 2005;352:1977-1984.
5. D'Amico AV, Chen MH, Roehl KA, Catalona WJ. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med. 2004;351:125-135.
6. D'Amico AV, Renshaw AA, Sussman B, Chen MH. Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy. JAMA. 2005;294:440-447.
7. Thompson IM, Ankerst DP, Chi C, et al. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst. 2006;98:529-534.
8. Carter HB, Pearson ID, Metter EJ, et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA. 1992;267:2215-2220.
9. Smith DS, Catalona WJ. Rate of change in serum prostate specific antigen levels as a method for prostate cancer detection. J Urol. 1994;152:1163-117.
10. Pinsky PF, Andriole G, Crawford ED, et al. Prostate-specific antigen velocity and prostate cancer Gleason grade and stage. Cancer. 2007;109:1689-1695.
11. Sun L, Gancarczyk K, Paquette EL, et al. Introduction to Department of Defense Center for Prostate Disease Research Multicenter National Prostate Cancer Database, and analysis of changes in the PSA-era. Urol Oncol. 2001;6:203-209.
12. Gleason DF, Group VACUR. Histologic grading and staging of prostatic carcinoma. In: Tannenbaum M, ed. Urologic Pathology. Philadelphia, Pa: Lea & Febiger; 1977:171-187.
13. Punglia RS, D'Amico AV, Catalona WJ, Roehl KA, Kuntz KM. Effect of verification bias on screening for prostate cancer by measurement of prostate-specific antigen. N Engl J Med. 2003;349:335-342.
14. Simultaneous inferences and other topics in regression analyses-1. In: Kutner M, ed. Applied Linear Regression Models. Homewood, Ill: Richard D. Irwin; 1983:150-153.
15. Llorente MD, Burke M, Gregory GR, et al. Prostate cancer: a significant risk factor for late-life suicide. Am J Geriatr Psychiatry. 2005;13:195-201.